Gallbladder cancer is a rare disease that often arises in the setting of chronic inflammation. The American Cancer Society estimates that approximatel 12,360 new cases of gallbladder cancer and cancers of nearby large bile ducts will be diagnosed in 2019.[1]
The image below is a schematic drawing of the extent of lymphadenectomy for gallbladder cancer.
View Image
A schematic drawing of the extent of lymphadenectomy for gallbladder cancer, especially when the extrahepatic biliary tree is resected.
Signs and symptoms
Signs and symptoms are usually not present until the later stages of gallbladder cancer and may include the following:
Jaundice
Pain above the stomach
Fever
Nausea and vomiting
Bloating
Lumps in the abdomen
Jaundice, anorexia, and weight loss often indicate more advanced disease.
See Presentation for more detail.
Diagnosis
Gallbladder cancer is difficult to detect and diagnose. Signs and symptoms are not usually seen in the early stages of disease and often overlap with the symptoms of gallstones and biliary colic.
Laboratory studies
Some tests that may prove helpful in diagnosing gallbladder cancer include the following:
Liver function tests
CA 19-9 assay
Carcinoembryonic antigen (CEA) assay
Imaging studies
Ultrasonography (US) is a standard initial study in patients with right upper quadrant pain. A mass can be identified in 50-75% of patients with gallbladder cancer.
Computed tomography (CT) scans also may be useful in patients with upper abdominal pain and can demonstrate tumor invasion outside of the gallbladder and identify metastatic disease elsewhere in the abdomen or pelvis.
Percutaneous transhepatic cholangiography (PTC) or endoscopic retrograde cholangiography (ERCP) may establish the diagnosis of gallbladder cancer by bile cytology. Magnetic resonance cholangiopancreatography (MRCP) is a noninvasive way to take images of the bile ducts using the same type of machine used for standard MRI scans.
Staging
The following stages are used for gallbladder cancer:
Stage 0 (carcinoma in Situ) : Abnormal cells are found in the inner (mucosal) layer of the gallbladder; these abnormal cells may become cancer and spread into nearby normal tissue [#Keypoint11]
Stage I : Cancer has formed and has spread beyond the inner (mucosal) layer to a layer of tissue with blood vessels or to the muscle layer
Stage II : Cancer has spread beyond the muscle layer to the connective tissue around the muscle.
Stage IIIA : Cancer has spread through the thin layers of tissue that cover the gallbladder and/or to the liver and/or to one nearby organ (eg, stomach, small intestine, colon, pancreas, or bile ducts outside the liver)
Stage IIIB : Cancer has spread to nearby lymph nodes and beyond the inner layer of the gallbladder to a layer of tissue with blood vessels or to the muscle layer; or beyond the muscle layer to the connective tissue around the muscle; or through the thin layers of tissue that cover the gallbladder and/or to the liver and/or to one nearby organ
Stage IVA : Cancer has spread to a main blood vessel of the liver or to 2 or more nearby organs or areas other than the liver. Cancer may have spread to nearby lymph nodes.
Stage IVB : Cancer has spread to either lymph nodes along large arteries in the abdomen and/or near the lower part of the backbone or to organs or areas far away from the gallbladder.
See Workup for more detail.
Management
The main types of treatments used for gallbladder cancer include the following:
Surgery
Radiation therapy
Chemotherapy
Palliative therapy
Although complete surgical resection is the only therapy to afford a chance of cure, en bloc resections of the gallbladder and portal lymph nodes carry a high morbidity and mortality (similar to bile duct carcinoma). Nodal metastases outside of the regional area (ie, porta hepatis, gastrohepatic ligament, retroduodenal area) are not resectable.
Cancers of the biliary tract include cholangiocarcinoma (cancers arising from the bile duct epithelium), ampulla of Vater cancer, and gallbladder cancer. All subtypes of biliary tract cancers are rare and have an overall poor prognosis. They are also difficult to diagnose. These diseases are often discussed together and are mingled in therapeutic trials. However, this leads to significant confusion.
Gallbladder cancer is the fifth most common gastrointestinal (GI) cancer in the United States.[2] Worldwide, it is the sixth most common GI cancer and the most common biliary tract malignancy, accounting for 80%–95% of biliary tract cancers.[3] About 20% arise from the extrahepatic biliary tract and 20% arise from the ampulla of Vater.[4] Despite some similarities, gallbladder cancer is a distinct clinical entity and will be discussed exclusively in this article.
Gallbladder cancer arises in the setting of chronic inflammation. In the vast majority of patients (>75%), the source of this chronic inflammation is cholesterol gallstones. The presence of gallstones increases the risk of gallbladder cancer 4- to 5-fold.[5] Other more unusual causes of chronic inflammation are also associated with gallbladder cancer. These causes include primary sclerosing cholangitis, ulcerative colitis,[6] liver flukes, chronic Salmonella typhi and paratyphi infections,[7] and Helicobacter infection.[8]
However, chronic gallbladder inflammation is likely only part of the cause of the malignant transformation seen in gallbladder cancer. Many other factors have been identified. Ingestion of certain medications (eg, oral contraceptives, INH, methyldopa) can increase the risk of gallbladder cancer. Likewise, certain chemical exposures (eg, pesticides, rubber, vinyl chloride) and occupational exposures associated with working in the textile, petroleum, paper mill, and shoemaking industries increase the risk of gallbladder cancer.
In addition, exposures through water pollution (organopesticides, eg, dichlorodiphenyltrichloroethane and benzene hexachloride); heavy metals (eg, cadmium, chromium, lead); and radiation exposure (eg, radon in miners) are associated with gallbladder cancer. Obesity[9] may contribute to gallbladder cancer through its association with gallstones, its association with increased endogenous estrogens, or through the ability of fat cells to secrete alargenumberofinflammatorymediators.[4]
An increased incidence of gallbladder cancer also occurs in hereditary syndromes including the following[4] :
Gardner syndrome
Neurofibromatosis type I
Hereditary nonpolyposis colon cancer
The role of various oncogenic mutations in gallbladder cancer is an area of active research. For example, a small study of gallbladder cancer from Japan reported an excess risk associated with polymorphism of the cytochrome P450 1A1 gene (CYP1A1), which encodes a protein involved in catalyzing the synthesis of cholesterol and other lipids.[10] Another study looked at polymorphisms within the apolipoprotein B gene.[11]
A case-control genome-wide association study from India identified common genetic variations that confer gallbladder cancer risk at genome-wide significance. Substantial variation in risk was associated with single-nucleotide polymorphisms involving the hepatobiliary phospholipid transporter genes ABCB1 and ABCB4, suggesting a role for those genes in the pathology of gallbladder cancer.[12]
Wu et al retrospectively analyzed surgical specimens from 97 consecutive gallbladder cancer patients treated in Taiwan between 1993 and 2005 at 2 tertiary medical centers for alpha-methylacyl coenzyme A racemase (AMACR) expression. The authors found that overexpression of this enzyme in gallbladder cancer was associated with a more advanced T stage, a higher histologic grade and vascular invasion. Overexpression of AMACR was also found to be an independent predictor of decreased disease-specific survival in this group of patients.[13]
Abnormal anatomy such as congenital defects with anomalous pancreaticobiliary duct junctions and choledochal cysts increase the risk of gallbladder cancer.[14, 15] The tumor is usually located in the fundus of the gallbladder. Local spread through the gallbladder wall can lead to direct liver invasion, or, if in the opposite direction, leads to transperitoneal spread (20% of patients at presentation), with implants on the liver, on the bowel, and in the pelvis. Tumor may also directly invade other adjacent organs such as the stomach, duodenum, colon, pancreas, and extrahepatic bile duct.
At diagnosis, the gallbladder is often replaced or destroyed by the cancer. In addition, approximately 50% of patients have regional lymph node metastases.
See the Gallbladder and Biliary Disease Resource Center for more information about related conditions.
Gallbladder cancer incidence increases with age and is more common in women. Approximately 12,360 new cases—5810 in men and 6550 in women—of cancer of the gallbladder and nearby large bile ducts are predicted for 2019, with fewer than 4 in 10 of them gallbladder cancers, according to the American Cancer Society. Approximately 3960 deaths are projected for 2019, 1610 in men and 2350 in women.[1]
In the United States, incidence varies substantially with racial and ethnic group and sex. Gallbladder cancer rates are the highest among American Indians/Alaska Natives and among white Hispanic peoples. Within both groups, incidence of gallbladder cancer is significantly higher in women.[4] The white Hispanic female incidence rate is 4.2 per 100,000 person-years. The American Indian/Alaskan Native female incidence rate is 4.1 per 100,000 person-years. The corresponding male rates are 1.4 and 3,3 per 100,000 person-years, respectively. The lowest incidence rate for gallbladder cancer is among non-Hispanic white males and is 0.7 per 100,000 person-years.
The incidence of gallbladder cancer rises with age. Seventy-five percent of patients with gallbladder cancer are older than 64 years.[1] In non-Hispanic whites and blacks, the rate of gallbladder cancer rises more slowly than among Hispanic whites and American Indian/Alaskan Natives. The rates for gallbladder cancer are higher among women than men in all age groups.[4]
Overall, the incidence (cases per year) has dropped by more than 50% in the general population since 1973. In Native American women, the incidence has decreased by 70%.[1]
International
Considerable variation exists in the incidence of gallbladder cancer throughout the world. Areas with the highest incidence rates include India, Korea, Japan, Czech Republic, Slovakia, Spain, Columbia, Chile, Peru, Bolivia, and Ecuador. The high incidence rates reported in Peru and Chile are thought to reflect the Hispanic populations with Indian heritage. Women from India have the highest international rate of gallbladder cancer, at between 8.8 per 100,000 person-years and 21.2 per 100,000 person-years.[4, 7] The United Kingdom, Denmark, and Norway have the lowest international incidence rates. Gallbladder cancer is the most common cancer affecting women in Chile.
Survival is correlated with staging based on the American Joint Committee on Cancer (AJCC) tumor, node, metastases (TNM) staging system.[16] Most patients have regional disease or distant metastases at presentation. Therefore, the prognosis in gallbladder disease is poor, with 5-year survival rates of 15-20%.[4]
Patients with stage IA disease (T1N0M0) should be cured with a simple cholecystectomy. In selected surgical series, patients with stage IB (T2N0M0) disease treated with extended cholecystectomy have a 5-year survival rate of 70-90%, and patients with stage IIB (T1-3N1M0) treated with extended cholecystectomy have a 5-year survival of 45-60%. Stage III (T4, any N, M0) gallbladder cancer is generally not surgically curable. The 1-year survival rate for advanced gallbladder cancer is less than 5%. The median survival is 2-4 months.
The SEER registry from 1995-2001 shows 5-year survival rates for localized gallbladder cancer of approximately 40%. The 5-year survival rate for regional disease is listed at approximately 15%, and the 5-year survival rate for distant metastatic disease is reported at less than 10%.[3] However, survival data are variable from institution to institution for each stage.
Unfortunately, only about 10-20% of patients present with tumor confined to the gallbladder wall. At diagnosis, 40-60% of patients have lesions that perforate the gallbladder wall and invade adjacent organs (T3) and 45% of patients have regional lymph node involvement (N1). Approximately 30% of patients present with metastatic disease.
Race-, sex-, and age-related demographics
The highest rates of gallbladder cancer in the US are found in the US Native American and Hispanic, especially Mexican, populations. A substantial female predominance exists in the US and worldwide, with female-to-male ratios of approximately 2.5:1 to 3:1. Gallbladder cancer is most typically diagnosed in the seventh decade of life, with a median age of 62-66 years.
The symptoms of gallbladder cancer overlap with the symptoms of gallstones and biliary colic. Abdominal pain may be of a more diffuse and persistent nature than the classic right upper quadrant pain of gallstone disease. Jaundice, anorexia, and weight loss often indicate more advanced disease.[17]
Measurement of tumor marker CA 19-9 may be helpful in the appropriate situation if the clinical suspicion for gallbladder cancer is high. CA 19-9 levels may be significantly elevated in both cholangiocarcinoma and gallbladder cancer. CA 19-9 measurement can also be useful in conjunction with carcinoembryonic antigen (CEA) assays.
The relevance of other laboratory tests is as follows:
Liver function tests: Elevated alkaline phosphatase and bilirubin levels are often found with more advanced disease.
Blood urea nitrogen (BUN), creatinine, urinalysis: Assess renal function prior to performing an enhanced CT scan.
Complete blood cell count (CBC): Anemia may be an indicator of more advanced disease.
Ultrasonography (US) is a standard initial study in patients with right upper quadrant pain. A mass can be identified in 50-75% of patients with gallbladder cancer. It also can delineate metastatic lesions in the liver.
Computed tomography (CT) scans also may be useful in patients with upper abdominal pain and can demonstrate tumor invasion outside of the gallbladder and identify metastatic disease elsewhere in the abdomen or pelvis. Liver invasion occurs in 60% of cases, and the combination of CT scan and US provides accurate details of disease extension. However, a study of multi-detector CT (MDCT) found that MDCT has moderate sensitivity, poor specificity, and moderate-to-substantial inter-rater repeatability for differenting gallbladder cancer from acute and xanthogranulomatous cholecystitis.[18]
Magnetic resonance imaging (MRI) has been useful in examining this region for disease extension into other tissues or metastatic disease in the liver. It can provide details of the vasculature for preoperative planning via magnetic resonance angiogram (MRA) and bile duct passages via magnetic resonance cholangiogram (MRCP).
A systematic review and meta-analysis of diffusion-weighted MRI reported a pooled sensitivity of 91% and a pooled specificity of 87% for differentiating benign from malignant gallbladder lesions. The authors recommended obtaining thinner image slices (≤5 mm) with 3T field strength and performing qualitative assessment in order to enhance the diagnostic ability of diffusion-weighted imaging.[19]
Cholangiography, via a percutaneous route, or endoscopic retrograde cholangiography (ERCP) may establish the diagnosis of gallbladder cancer by bile cytology.
Endoscopic ultrasonography can be useful to assess regional lymphadenopathy and depth of tumor invasion into the wall of the gallbladder. In conjunction with other studies, it also can provide a means of obtaining bile for cytologic analysis, which has a sensitivity of 73% for the diagnosis of gallbladder cancer.[20]
Angiography may be used to confirm encasement of the portal vein or hepatic artery and may assist in preoperative planning for definitive resection.
A routine chest radiograph should also be obtained.
ERCP can demonstrate the site of the obstruction by direct retrograde dye injection, as well as exclude ampullary pathology by endoscopic evaluation. Brush cytology, biopsy, needle aspiration, and shave biopsies via ERCP can provide material for histology. Palliative stenting to relieve biliary obstruction can be performed at the time of the evaluation.
Percutaneous transhepatic cholangiography (PTC) may allow access to the proximal biliary tree that has become obstructed by extensive tumor growth from the gallbladder. Material for cytology can be obtained and drainage performed as well.
Other methods to obtain tissue include CT or ultrasound needle aspiration if a mass lesion is present and endoscopic ultrasonographic (EUS) fine-needle aspiration.
Adenocarcinoma is the primary histologic finding in 80-85% of gallbladder carcinomas, with several histologic subtypes, including papillary, nodular, and infiltrative. The papillary type appears to be less aggressive and more often localized and has a better prognosis than the other forms. Additional rare histologic types of gallbladder cancer exist. These include squamous cell cancer, sarcomas, carcinoid, lymphoma, and melanoma.
Grade is also important, with poorly differentiated tumors associated with a poorer prognosis than the typically less infiltrative, better differentiated tumors with metaplasia.
Staging of tumor extent is essential in selection of the appropriate treatment approach.
The AJCC 6th edition guidelines follow the TNM system, with depth of tumor penetration and regional spread defined pathologically.[16] Survival is correlated directly with stage of disease.
Primary tumor
Category T
TX - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ
T1 - Tumor invades lamina propria or muscle layer
T1a - Tumor invades lamina propria
T1b - Tumor invades muscle layer
T2 - Tumor invades perimuscular connective tissue; no extension beyond serosa or into liver
T3 - Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts
T4 - Tumor invades main portal vein or hepatic artery or invades multiple extrahepatic organs or structures
Regional lymph node
Category N
NX - Regional lymph nodes cannot be assessed
N0 - No metastases in regional lymph nodes
N1 - Metastases to regional lymph nodes along the cystic duct, common bile duct, hepatic artery, and/or portal vein
N2 - Metastases to periaortic, pericaval, superior mesenteric artery, and/or celiac artery lymph nodes
Although complete surgical resection is the only therapy to afford a chance of cure, en bloc resections of the gallbladder and portal lymph nodes carry a high morbidity and mortality (similar to bile duct carcinoma). Adequate surgical margins may be difficult to achieve. The role of adjuvant radiation therapy is to control microscopic residual deposits of carcinoma in the tumor bed and regional lymph nodes. The rationale for radiation therapy with or without concurrent chemotherapy in patients with unresectable disease is to provide palliation of symptoms. Rarely, it may increase survival.
The role of radiotherapy for carcinoma of the gallbladder is unclear because the available literature is derived from small, single institutional experiences over many years, with a variety of treatment methods used. Complicating this is the fact that only approximately 25% of patients with carcinoma of the gallbladder can undergo curative surgery.
Even large institutions do not accrue more than single-digit numbers of patients per year, and many are not on protocol. Available reports contain small numbers of patients with incomplete reporting of technical treatment data, histological grading, and tumor extent. The literature is strongly biased by patient selection, and interpretation of the reports is difficult. Given these difficulties, the data support the following statements:
Radiotherapy has been delivered in a variety of situations, including after curative resections with close or positive microscopic margins, gross macroscopic residual disease, and palliative debulking with bypass.
Significant increases in survival rates have been reported after curative surgery is attempted and only microscopic residual disease remains. Survival in these patients after surgery alone ranges from 6-7 months and can be prolonged to longer than 12 months with external beam radiotherapy administered as adjuvant therapy. This excludes patients with T1 or stage I disease confined to the mucosa of the gallbladder. Their survival rates are extremely high and they are at very low risk for lymph node metastases.
All patients with tumors beyond the mucosa are candidates for external beam radiotherapy. Patients with curative resection and AJCC stages T2-T4 who have had complete resection who receive radiation have a mean survival of over 16 months. This is compared to less than 6 months mean survival with surgery alone.
5-FU–based chemotherapy is usually given in conjunction with concurrent radiation therapy in the adjuvant setting. Adjuvant chemotherapy can be given with single agent gemcitabine or a fluorpyrimidine-based agent. No evidence-based clinical study exists to demonstrate the benefit of any form of adjuvant therapy in gallbladder cancer. Wherever possible, patients eligible for adjuvant therapy should be entered in a clinical trial. Gemcitabine by itself is an effective agent in the treatment of patients with unresectable recurrent or metastatic disease. The combination of gemcitabine and cisplatin[21] or the combination of gemcitabine and capecitabine may be more effective than gemcitabine alone.
In a randomized, controlled, single institution study from India, Sharma et al compared best supportive care versus 5FU/leucovorin or gemcitabine/oxaliplatin in 81 patients with unresectable gallbladder cancer. The gemcitabine/oxaliplatin treatment arm was statistically superior in terms of overall response rate, median overall survival, and progression-free survival.[22]
In the UK ABC-02 trial,[23] a multicenter, phase III randomized trial, gemcitabine plus cisplatin demonstrated a survival advantage over gemcitabine alone. The median overall survival was11.7 months for those receiving gemcitabine plus cisplatin compared with 8.1 months for those receiving gemcitabine alone; progression-free survival was 8 months in the group receiving gemcitabine plus cisplatin group compared with 5 months in those receiving only gemcitabine.
Because some patients are not able to receive cisplatin-based chemotherapy, Iqbal et al explored gemcitabine plus capecitabine as a possible treatment option in a phase 2 study of 57 patients with advanced or metastatic biliary cancer. This study included both patients with cholangiocarcinoma (67%) and patients with gallbladder cancer (33%). No complete responses were seen. Of the 52 patients who were able to continue the study, a confirmed partial response was seen in 7 patients, and an unconfirmed partial response was seen in 6 patients. Stable disease was seen in 12 patients. Six-month overall survival was 55%, and median survival was 7 months. Of the 51 patients available for toxicity assessment, 6 had grade 4 toxicities. The study concluded that the combination of gemcitabine and capecitabine was well-tolerated.[24]
Because EGFR is overexpressed in a vast majority of biliary tract cancers, trials using EGFR-targeting agents have occurred. The BINGO trial, a phase II clinical trial of 101 patients (24% with gallbladder cancer), compared gemcitabine with oxaliplatin (GEMOX), alone or in combination with cetuximab; an interim analysis demonstrated a benefit for the GEMOX plus cetuximab arm, with a progression-free survival of 5 months compared with 7 months in the other arm.[25]
In support of this, a 30-patient, single-arm, phase II trial also evaluated the role of cetuximab with GEMOX in patients with unresectable advanced or metastatic biliary cancer (10% with gallbladder cancer).[26] An improvement in progression-free survival and overall survival was seen (progression-free survival, 8.8 mo; median overall survival, 15.2 mo). Wild-type KRAS was found in 90% of patients; however, all 3 patients who had tumors with KRAS mutations responded to therapy. Although the data are encouraging, more definitive phase III clinical trials are needed to direct therapy for patients with this particular malignancy.
Selected patients with unresectable disease may be considered for surgical resection after response to chemotherapy. This is based on a retrospective study showing markedly improved survival in a small number of patients who received gemcitabine and cisplatin followed by surgery.[27] More trials are needed to evaluate this benefit.
Patients with a good performance status should be considered for a clinical trial or for treatment with the regimens described in this section. Patients with a poor performance status may be best treated with supportive care.
Complete surgical resection is the only therapy to offer a chance of cure in this disease. Unfortunately, only a minority of patients present with early-stage disease and are, therefore, considered for curative resection.
Optimistically, 5 year survival rates for gallbladder cancer have increased 5-12% up to 38%. This increase is felt to be related to a trend in standardizing aggressive approaches to locally confined disease.[28] Studies evaluating the significance of tumor involvement of the liver in early T-stage tumors and lymph node metastases on outcomes suggest that a need to standardize minimum requirements for adequate surgical resection and pathological examination of gallbladder cancer resections.[29]
Patients who present with a gallbladder mass or jaundice are evaluated preoperatively for resectability, including chest imaging, abdominal/ pelvic CT scan, or MRI and possibly a staging laparoscopy. Nodal metastases outside of the regional area (ie, porta hepatis, gastrohepatic ligament, retroduodenal area) are not resectable. If the tumor is resectable, the patient should undergo a cholecystectomy, hepatic resection, and regional lymphadenectomy (see the image below). The extent of hepatic resection is currently undefined. However, approximately 25% of T2 tumors have liver involvement. Liver involvement is a prognostic indicator of worse outcome.[29] Bile duct excision may also be necessary, especially if jaundice is present. The operative morbidity and mortality rate increases with the complexity of the operative procedure.
View Image
A schematic drawing of the extent of lymphadenectomy for gallbladder cancer, especially when the extrahepatic biliary tree is resected.
Gallbladder cancer is sometimes an incidental pathology finding after a cholecystectomy is performed for reasons other than cancer. If the tumor is carcinoma in situ (Tis) or only invades the lamina propria (T1a) and the margins of resection are negative, then postoperative observation alone is acceptable. If the tumor is T1b or greater or the margins of resection are positive and if no metastatic disease is present on evaluation (CT or MRI scan and chest radiograph), then a second surgical resection is required. This additional surgery should include partial hepatic resection and regional lymphadenectomy (porta hepatis, gastrohepatic ligament, and retroduodenal lymph nodes). A bile duct resection may also be necessary, depending on tumor size and location. If the original surgery was performed via a laparoscopic approach, then the port sites should also be resected to avoid tumor seeding.
Because of the high incidence of gallbladder cancer in a calcified (porcelain) gallbladder, patients with this finding should be strongly considered for an open cholecystectomy, even if they are asymptomatic. Avoid a laparoscopic cholecystectomy in this setting to avoid the risk of peritoneal seeding if, indeed, gallbladder cancer is present.
Lymph node evaluation is a critical component of radical resections for gallbladder cancer and has been shown to improve survival in a recent retrospective trial.[30] Although no consensus has been reached on the minimum number of lymph nodes required for evaluation for accurate staging, one study demonstrated in a prospectively maintained database that patients with an R0 resection who were determined to be N0 based on total lymph node count (TLNC) of 6 or more had a relapse free (RFS) and disease specific survival (DSS) rates of 70% and 72%, respectively. Patients with an R0 resection who were determined to be N0 based on a TLNC of less than 6 had RFS and DSS rates of 32% and 45%, respectively. This underscores the importance in a thorough lymphadenectomy of the porta hepatis and complete review of the pathological specimens for accurate risk stratification of patients with gallbladder cancer.
The surgical role in treatment of unresectable disease is usually limited to biopsy of the tumor for diagnosis and possible biliary decompression procedures.
A radiation oncologist and medical oncologist should be part of the multidisciplinary team participating in the treatment of patients with gallbladder cancer.
Guidelines Contributor: Elwyn C Cabebe, MD Physician Partner, Valley Medical Oncology Consultants; Medical Director of Oncology, Clinical Liason Physician, Cancer Care Committee, Good Samaritan Hospital
Diagnosis
According to the National Comprehensive Cancer Network (NCCN) guidelines, gallbladder cancer may be diagnosed as an incidental finding in patients who undergo laparoscopic cholecystectomy, either at surgery or on pathologic review. In such cases, the NCCN recommends postoperative imaging with multiphasic abdominal and pelvic computed tomography (CT) or magnetic resonance imaging (MRI) with intravenous contrast and chest CT with or without contrast. In cases that are an incidental finding on pathologic review, the NCCN also recommmends considering staging laparoscopy.[31]
For cases that present as a mass on an imaging study, the recommended workup includes the following:
History and physical examination
Multiphasic abdominal/pelvic CT/MRI with IV contrast
Chest CT with or without contrast
Liver function tests (LFTs) and assessment of hepatic reserve
Surgical consultation
Consider carcinoembryonic antigen (CEA) and CA 19-9 testing
For patients who present with jaundice, the recommended workup includes the following:
History and physical examination
Liver function tests and assessment of hepatic reserve
Chest CT with or without contrast
Multiphasic abdominal/pelvic CT/MRI with IV contrast
Cholangiography (preferably magnetic resonance cholangiopancreatography [MRCP])
Surgical consultation
Consider CEAl and CA 19-9 testing
Consider staging laparoscopy
The European Society of Medical Oncology clinical practice guidelines for biliary cancer published in 2016 recommend diagnosis on the basis of MRI with MRCP contrast-enhanced and diffusion-weighted imaging. CT was deemed less useful. Pathological diagnosis is required before any nonsurgical therapy, but is not critical in patients with characteristic findings of resectable tumors. Endoscopic retrograde cholangiopancreatography (ERCP)–guided biopsies are preferred to biliary brush cytology.[32]
In 2013, the American Society for Gastrointestinal Endoscopy (ASGE) released guidelines for the use of endoscopy in the evaluation of biliary neoplasia. The recommendations for gallbladder polyps included the following[33] :
Endoscopic ultrasound (EUS) or fine-needle aspiration (FNA) if the results would change the management
Cholecystectomy for symptomatic patients with gallbladder polyps, asymptomatic patients with gallbladder polyps >10 mm, and any patient with gallbladder polyps and primary sclerosing cholangitis
Asymptomatic patients with gallbladder polyps ≥6 mm but no other risk factors for gallbladder cancer should receive annual transabdominal ultrasound screening
Staging
Gallbladder cancer staging follows the tumor-node-metastasis (TNM) classification of the American Joint Cancer Committee/Union for International Cancer Control/ (AJCC/UICC) and is classified into four stages based on the depth of invasion into the gallbladder wall and the extent of spread to surrounding organs and lymph nodes.[16]
TNM groupings by stage are as follows:
Stage 0- Tis N0 M0
Stage I - T1 N0 M0
Stage IIA - T2a N0 M0
Stage IIB - T2b N0 M0
Stage IIIA - T3 N0 M0
Stage IIIB - T1-3 N1 M0
Stage IVA - T4 N0-1 M0
Stage IVB - Any T Any N M1
Treatment
The NCCN guidelines include the following recommendations for resectable disease[31] :
Simple cholecystectomy for T1a lesions (limited to the mucosa)
Staging laparoscopy, followed immediately (in the same session) by definitive resection; biopsy is not required
For patients with T1b or greater lesions, radical cholecystectomy and lymphadenectomy with or without bile duct excision; hepatic resection is performed to obtain clear margins, which usually consists of segments IV B and V but may need to be extended beyond that in some patients
For patients with suspicious mass on imaging or with jaundice, cholecystectomy plus en bloc hepatic resection and lymphadenectomy with or without bile duct excision
Jaundice that is not amenable to drainage is considered a relative contraindication to surgery; only a portion of those with node-negative disease potentially benefit from complete resection; surgery should only be performed with curative intent
Fluoropyrimidine-based chemoradiotherapy, or fluoropyrimidine or gemcitabine chemotherapy alone may be considered for adjuvant treatmen, except for individuals with resected T1a or T1b N0 tumors
The 2016 ESMO guidelines recommendations for resectable disease include the following[32] :
Every T-stage above T1a and positivity of any mentioned parameters requires a reoperation and a segment IVb/V liver resection with a ligamentary lymphadenectomy
If the gallbladder was not removed with a bag during laparoscopic resection or the gallbladder perforated (an adverse prognostic factor), the port sites should also be resected
When patients present with jaundice, evaluation of potential resectability is needed
Advanced T-stage (including T4 tumors) is not a contraindication for resection provided they are located in the fundus; these tumors require major liver resection with potential resection of the transverse colon.
Achieving a curative resection of an advanced tumor located at the infundibulum requires the resection of the bile duct, the duodenal bulb and, potentially, the pancreatic head together with a major hepatectomy, especially if right-sided vessels (right hepatic artery, right portal vein) are involved
For management of patients with unresectable or metastatic disease, NCCN makes the following recommendations[31] :
Historically, chemotherapy has not shown significant activity in gallbladder carcinoma. Typically, 5-fluorouracil (5-FU) has been used with response rates of 10-24% in advanced disease. Often 5-FU is administered either as a bolus or as a prolonged infusion regimen with radiation. Capecitabine is a currently available oral alternative to a prolonged 5-FU infusion.
More recently, gemcitabine has shown activity in gallbladder cancer. Early-phase studies show an increased response rate with gemcitabine combination therapy over historical treatment response rates with 5-FU alone. Gemcitabine has been studied in combination with cis-platinum and capecitabine.
Currently, no clearly defined standard exists for chemotherapy in gallbladder cancer. Patients should be encouraged to participate in clinical trials.
Clinical Context:
Cytidine analog, after intracellular metabolism to active nucleotide, inhibits ribonucleotide reductase and competes with deoxycytidine triphosphate for incorporation into DNA. Cell cycle-specific for S phase.
This drug has been shown to have activity in a phase-2 trial against relapsed germ cell tumors.
Clinical Context:
Platinum-containing compound that exerts antineoplastic effect by covalently binding to DNA with preferential binding to N-7 position of guanine and adenosine. Can react with 2 different sites on DNA to cause cross-links. Platinum complex also can bind to nucleus and cytoplasmic protein. A bifunctional alkylating agent, once activated to aquated form in cell, binds to DNA, resulting in interstrand and intrastrand cross-linking and denaturation of double helix.
Modify dose on basis of CrCl. Avoid use if CrCl < 60 mL/min.
Clinical Context:
Prodrug of fluorouracil that undergoes hydrolysis in liver and tissues to form the active moiety (fluorouracil), inhibiting thymidylate synthetase, which in turn blocks methylation of deoxyuridylic acid to thymidylic acid. This step interferes with DNA, and to a lesser degree with RNA synthesis.
Because survival is usually very short in patients with advanced disease, close follow-up is essential to preserve the best quality of life. For patients with earlier stage disease who are treated with surgery and postoperative radiation therapy and chemotherapy, intermittent posttreatment imaging studies can be considered (particularly in the first few years).
Hospice referral is important early in the disease course for patients with metastatic disease because their survival is typically 6 months or less.
Because a calcified (porcelain) gallbladder has up to a 25% incidence of associated gallbladder cancer, this is an indication for a cholecystectomy even in an asymptomatic patient.
A small percentage (< 10%) of patients with gallbladder polyps are found to have underlying gallbladder cancer. The risk increases with age and the size of the polyp. A cholecystectomy should be considered if a gallbladder polyp greater than 1 cm in size is found in a patient older than 50 years.
Survival at 5 years is correlated with stage of disease at presentation. Only 10-20% of patients present with localized disease. The remainder present with regional or distant spread. From 1989 to 1996, 5-year survival in patients with primary gallbladder cancer was 50% for stage I disease and 2% for stage IV disease.[34]
How common is gallbladder cancer?What are the signs and symptoms of gallbladder cancer?Which lab tests are performed in the workup of gallbladder cancer?What is the role of imaging studies in the diagnosis of gallbladder cancer?How is gallbladder cancer staged?How is gallbladder cancer treated?What are biliary tract cancers and what is their prognosis?How common is gallbladder cancer?What is the pathophysiology of gallbladder cancer?What is the role of genetics in the pathophysiology of gallbladder cancer?What is the role of alpha-methylacyl coenzyme A racemase (AMACR) expression in the pathophysiology of gallbladder cancer?What is the role of anatomy in the pathophysiology of gallbladder cancer?What is the incidence of gallbladder cancer in the US?What is the global prevalence of gallbladder cancer?What are the mortality rates for gallbladder cancer?Which patient groups are at highest risk for gallbladder cancer?Which clinical history findings are characteristic of gallbladder cancer?Which physical findings are characteristic of gallbladder cancer?Which conditions are associated with gallbladder cancer?What are the differential diagnoses for Gallbladder Cancer?What is the role of lab studies in the workup of gallbladder cancer?What is the role of imaging studies in the workup of gallbladder cancer?What is the role of ERCP in diagnosis of gallbladder cancer?What is the role of percutaneous transhepatic cholangiography (PTC) in diagnosis of gallbladder cancer?What is the role of imaging-assisted fine-needle aspiration in the diagnosis of gallbladder cancer?Which histologic findings are diagnostic of gallbladder cancer?How is gallbladder cancer staged?How are primary tumors staged in gallbladder cancer?How are lymph nodes staged in gallbladder cancer?How are metastases staged in gallbladder cancer?What are the tumor-node-metastasis (TNM) stages for gallbladder cancer?How is gallbladder cancer treated?What is the role of surgery in the treatment of gallbladder cancer?Which specialist consultations are beneficial for patients with gallbladder cancer?What are the NCCN treatment guidelines for resectable gallbladder cancer?What are NCCN guidelines for the evaluation of gallbladder cancer?What are the ESMO diagnostic guidelines for gallbladder cancer?What are the ASGE guidelines for evaluation of gallbladder polyps?What is the TNM staging for gallbladder cancer?What are the ESMO treatment guidelines for resectable gallbladder cancer?What are the NCCN treatment guidelines for unresectable or metastatic gallbladder cancer?What is the role of medications in the treatment of gallbladder cancer?Which medications in the drug class Antineoplastic agents are used in the treatment of Gallbladder Cancer?What is included in the long-term monitoring of gallbladder cancer?How is gallbladder cancer prevented?What is the prognosis of gallbladder cancer?
Mary Denshaw-Burke, MD, FACP, Clinical Assistant Professor of Medicine, Jefferson Medical College of Thomas Jefferson University; Clinical Assistant Professor, Affiliated Clinical Faculty of the Lankenau Institute for Medical Research; Program Director of Hematology/Oncology Fellowship, Education Coordinator for Oncology, Lankenau Medical Center
Disclosure: Nothing to disclose.
Coauthor(s)
Andrew Scott Kennedy, MD, Physician-in-Chief, Radiation Oncology
Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Benjamin Movsas, MD,
Disclosure: Nothing to disclose.
Chief Editor
N Joseph Espat, MD, MS, FACS, Harold J Wanebo Professor of Surgery, Assistant Dean of Clinical Affairs, Boston University School of Medicine; Chairman, Department of Surgery, Director, Adele R Decof Cancer Center, Roger Williams Medical Center
Disclosure: Nothing to disclose.
References
Key statistics for gallbladder cancer. American Cancer Society. Available at https://www.cancer.org/cancer/gallbladder-cancer/about/key-statistics.html. January 4, 2019; Accessed: December 12, 2019.
Valle JS, Wasan HS, Palmer DD, et al. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol. 2009 (suppl; abstr 4503). 27:15s.
Malka D, Trarbach T, Fartoux L, et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial. J Clin Oncol. 2009. 27(15 Suppl):Abstr 4520.
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. NCCN. Available at https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf. Version 3.2019 — August 1, 2019; Accessed: December 12, 2019.
){kind=link}